EFTA01118910Set 9
2012-10-3126p9,279w
account was reduced by 1501.930 fer the purchase of 16.535 Anad Pharmaceuticals & 2,095 Bingen IDEC.
on 5122112 the accounl was reduced by 61,330,000 for the purchase ... Anad PriannacetAcals at JPM 356.329 400,312 (43.963)
2.095 Bingen. IDEC at JPM 269050 312.595 (23,045)
8056048 0.255.419 (226 771)
JPM Trading (See attached) unrested 6.548.700 Net P812010
https://www.justice.gov/epstein/files/DataSet%209/EFTA01118910.pdf
EFTA01204597Set 9
2014-07-317p1,666w
6/25/14 250,000 0 076,406 9 370 000 9,760,000 683,594
Bingen Inc Inc 2/14/12 2.095 250.455 660,574 700.947 450,092
ricebook Inc 5/17/12
https://www.justice.gov/epstein/files/DataSet%209/EFTA01204597.pdf
EFTA01088033Set 9
2016-04-1921p9,988w
clients the common equity of the issuer on a principal basis: Alexion PharmaceuticsAmgen Inc, Bingen Inc., BioMarin. Celgene
Corp, Gilead Sciences Inc., Incyte Regeneron Pharrnaceut Vertex Pharmaceutics.
The issuer
https://www.justice.gov/epstein/files/DataSet%209/EFTA01088033.pdf
EFTA01199989Set 9
2014-12-317p1,459w
York Melon 6/25/14 250.000 , 9.078.408 10,007,500 10,14Z500 1,066,094
Bingen Idec Inc 2/14/12 2095
, 250455, 644611 711,148 460,693
ra ook Inc 5/17/12
https://www.justice.gov/epstein/files/DataSet%209/EFTA01199989.pdf